Tampa, FL 的 慢性淋巴性白血病 臨床試驗
8 項針對 慢性淋巴性白血病 的研究正在 Tampa（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Tampa General Hospital Cancer Institute, Tampa
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
招募中1/2 期
- Moffitt Cancer Center, Tampa
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Moffitt Cancer Center, Tampa
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- H. Lee Moffitt Cancer Center, Tampa
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Moffitt Cancer Center, Tampa
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
招募中觀察性研究
- Moffitt Cancer Center, Tampa
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- Moffitt Cancer Center, Tampa
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN18 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
Tampa 的其他研究
- 非小細胞肺癌51 項研究
- 乳癌43 項研究
- 癌症（所有類型）39 項研究
- 大腸直腸癌34 項研究
- 急性髓系白血病29 項研究
- 轉移性癌症29 項研究
- 肺癌29 項研究
- 胰臟癌26 項研究
- 卵巢癌21 項研究
- 黑色素瘤19 項研究
- 骨髓增生異常症候群19 項研究
- 前列腺癌18 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。